Fresenius Medical Care AG & Co. KGaA Investor News Investor Relations Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Te

Fresenius Medical Care Reports Strong Second Quarter and

Six Months 2007 Results and Raises Outlook for Full Year

Summary Second Quarter 2007:

Summary First Half 2007:

Bad Homburg, Germany Fresenius Medical Care AG & Co. KGaA ( the Company ), the world s largest provider of Dialysis Products and Services, today announced its results for the second quarter and first half 2007.

Second Quarter 2007:

Net revenue for the second quarter 2007 increased by 11% to $2,404 million (9% at constant currency) compared to the second quarter 2006. Organic revenue growth worldwide was 8%. Dialysis Services revenue grew by 9% to $1,796 million (8% at constant currency) in the second quarter of 2007. Dialysis Product revenue increased by 18% to $608 million (13% at constant currency) in the same period.

North America revenue increased by 6% to $1,660 million. Dialysis Services revenue grew by 5% to $1,499 million. Excluding effects of the divestiture of the perfusion business, Dialysis Service revenue increased by 6%. Average revenue per treatment for the U.S. clinics increased by 3% to $327 in the second quarter 2007 compared to $317 for the same quarter in 2006. Dialysis Product revenue increased by 21% to $161 million led by strong sales of our 2008K hemodialysis machines and the phosphate binding drug PhosLo.

International revenue was $744 million, an increase of 23% (15% at constant currency) compared to the second quarter of 2006. Dialysis Services revenue reached $296 million, an increase of 32% (24% at constant currency). Dialysis Product revenue rose by 17% to $448 million (10% at constant currency), led by strong sales of hemodialysis machines, peritoneal dialysis products and dialyzers.

Operating income (EBIT) increased by 5% to $391 million compared to $372 million in the second quarter 2006. Operating income for the second quarter 2006 includes costs of $4 million related to costs of restructuring and the transformation of the Company s legal form, and a gain of $39 million from the divestiture of dialysis clinics in conjunction with the acquisition of Renal Care Group. Excluding these costs and the gain from the divestiture, operating income for the second quarter 2007 increased by 16%, resulting in an operating margin of 16.3%. For the second quarter 2006 the operating margin was 15.5%.

In North America, compared with the second quarter 2006, the operating margin excluding the effects of one-time items increased by 140 basis points to 17.2% due to revenue rate improvements, the new PhosLo business and higher product sales which more than offset higher personnel expenses. In the International segment, the operating margin decreased by 50 basis points to 17.5% mainly due to higher growth in the dialysis care business.

Net interest expense for the second quarter 2007 was $92 million compared to $100 million in the same quarter of 2006. This positive development was mainly attributable to a lower debt level in combination with lower average interest rates.

Income tax expense was $113 million for the second quarter of 2007 compared to $137 million in the second quarter of 2006, reflecting effective tax rates of 38.0% and 50.6%, respectively. In the second quarter 2006, the tax rate had been impacted by a tax expense related to the gain on the divestiture of dialysis clinics in the U.S. Excluding this impact, the tax rate was at 40.2%.

Net income for the second quarter 2007 was $179 million, an increase of 38%. Net income increased by 30% when compared to the second quarter 2006 excluding the effects of one-time items in 2006.

Earnings per share (EPS)for the second quarter of 2007 rose by 37% to $0.60 per ordinary share compared to $0.44 for the second quarter of 2006. Earnings per ordinary American Depository Share (ADS) are the same as one ADS now represents one share

as a result of the change in ratio under the Company s ordinary shares and preference shares. The weighted average number of shares outstanding for the second quarter of 2007 was approximately 295.4 million shares compared to 293.9 million shares for the second quarter of 2006. The increase in shares outstanding results from stock option exercises in 2006 and in the first half 2007.

In the second quarter of 2007, the Company generated $225 million in cash from operations, representing 9% of revenue. The strong cash flow generation was primarily supported by earnings.

A total of $132 million was spent for

capital expenditures, net of disposals. Free Cash Flow before

acquisitions was $93 million compared to $145 million in the second quarter

of 2006 excluding the effects of the acquisition of RCG. A total of

$24 million in cash was used for acquisitions. Free Cash Flow

after acquisitions was $69 million compared to $121 million last year,

excluding the acquisition of Renal Care Group.

The operations of Renal Care Group (RCG) are included in the Company s consolidated statements of income and cash flows from April 1, 2006, therefore, the current first half year results are not directly comparable with the results of the first six months for 2006.

Revenue and Earnings

Net revenue was $4,725 million, up 21% from the first half of 2006. At constant currency, net revenue rose by 19%. Organic growth was 8% in the first six months of 2007.

Operating income (EBIT) increased by 23% to $756 million compared to $616 million in the first half of 2006. Operating income for the first half of 2006 includes costs of $4 million as a result of restructuring and the transformation of the Company s legal form, and a gain from the clinic divestitures of $39 million.

Excluding these items, operating income for the first half of 2007 increased by 30%. This performance resulted in an operating margin of 16.0% compared to 14.8% for the first half of 2006.

Net interest expense for the first six months of 2007 was $187 million compared to $156 million in the same period of 2006. The increase was the result of additional interest expense partially offset by the write-off in 2006 of deferred financing costs related to the 2003 senior credit facility of $15 million, both in conjunction with the financing of the RCG acquisition.

Income tax expense was $216 million in the first half of 2007 compared to $209 million in the same period in 2006, reflecting tax rates of 38.0% and 45.4%, respectively. The tax rate in the first half of 2006 was impacted by a tax expense related to the gain on the divestiture of dialysis clinics in the U.S. Excluding this impact, the effective tax rate in the first half of 2006 was at 39.2%.

For the first half of 2007, net income was $339 million, up 38% from the first half of 2006. Net income for the first half of 2007 increased by 29% compared to the first half of 2006 excluding the effects of one-time items in 2006.

For the first half of 2007, earnings per ordinary share rose by 37% to $1.15. The weighted average number of shares outstanding during the first half of 2007 was approximately 295.3 million.

Cash from operations during the first six months of 2007 was $508 million compared to $312 million for the same period in 2006 on a reported basis. Excluding the effects of one-time items, cash from operations was $402 million in the first half of 2006. The increase compared to prior year was mainly due to increased earnings.

A total of $240 million was used for capital expenditures, net of disposals. Free Cash Flow before acquisitions for the first six months of 2007 was $268 million compared to $152 million in same period in 2006. The underlying Free Cash Flow before acquisitions

and the effects of one-time items for the first half of 2006 was $242 million. A total of $114 million in cash was used for acquisitions.

Please refer to the attachments for a complete overview on the second quarter and first half 2007 and the reconciliation of non-GAAP financial measures included in this release to the most comparable GAAP financial measures.

Patients Clinics Treatments

As of June 30, 2007, Fresenius Medical Care treated 171,687 patients worldwide, which represents a 6% increase in patients compared to last year. North America provided dialysis treatments for 120,270 patients, an increase of 2%. Including 32 clinics managed by Fresenius Medical Care North America, the number of patients in North America was 122,199. The International segment served 51,417 patients, an increase of 17% over last year.

As of June 30, 2007, the Company operated a total of 2,209 clinics worldwide. This is comprised of 1,581 clinics in North America, an increase of 3%, and 628 clinics in the International segment, an increase of 17%.

Fresenius Medical Care delivered approximately 13.0 million dialysis treatments worldwide during the first six months of 2007. This represents an increase of 16% year over year. North America accounted for 9.08 million treatments, an increase of 16%, and the International segment delivered 3.92 million treatments, an increase of 17% over last year.

As of June 30, 2007, Fresenius Medical Care had 60,031 employees (full-time equivalents) worldwide compared to 56,803 employees at the end of 2006. The increase of 3,228 employees is primarily due to acquisitions in Asia and continued organic growth in the U.S.

The ratio of debt to Earnings before Interest, Taxes and Amortization (EBITDA) decreased from 3.60 at the end of the second quarter of 2006 to 3.03 at the end of the second quarter 2007. At the end of 2006, the debt/EBITDA ratio was 3.23.

In the second quarter 2007, Standard & Poor s Ratings Services raised its rating on the Company s senior secured debt to BBB- from BB+ . Standard & Poor s also upgraded the outlook for the Company s corporate rating from negative to stable .

Moody s upgraded the outlook for Fresenius Medical Care to positive from stable .

Issuance of 10 Year Senior Notes

At the beginning of the third quarter 2007, Fresenius Medical Care issued Senior Notes due 2017 in the amount of $500 million. The coupon is 6 7/8%. Proceeds were used to reduce indebtedness under the Company s senior secured bank credit facility and other, short-term debt. The Senior Notes were issued by FMC Finance III S.A., a wholly-owned subsidiary of the Company, and are guaranteed on a senior basis jointly and severally by the Company, Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care Deutschland GmbH.

Acquisition of a Production Plant in China

On July 17, 2007 Fresenius Medical Care acquired a production plant in Jiangsu, China from Bioteque Corp., Taipei, Taiwan. This plant currently produces bloodlines and other non-reusable products for the Chinese market and offers excellent additional opportunities to produce liquid and other non-reusable products for the Chinese market

and other countries in the region. In addition, the Company entered into three exclusive distribution contracts for marketing and distribution of Bioteque s bloodline and needle products in Taiwan, Korea and Japan.

Divestiture of Perfusion Business in the U.S.

Fresenius Medical Care sold the perfusion business unit of Fresenius Medical Care Extracorporeal Alliance ( FMCEA ) to Specialty Care Services Group, Inc. during the second quarter 2007. In 2006, FMCEA s perfusion business contributed revenue of approximately $110 million. The Company deconsolidated the U.S. perfusion business effective May 9, 2007.

On June 18, 2007, the previously announced share split for both classes of shares (ordinary and preference) in the ratio of 1:3 became effective. In connection with the share split, the ratio between the ordinary and preference ADS and the underlying ordinary and preference shares was adjusted to 1:1, meaning that one Fresenius Medical Care ordinary or preference ADS is now the equivalent of one Fresenius Medical Care ordinary or preference share.

Outlook for 2007 Upgraded

Based on the strong operational performance in the first half of 2007, the Company raises its outlook for the full year 2007 and now expects to achieve revenue of more than $9.5 billion. This represents an increase of at least 12%. Previously, the Company expected revenue of approximately $9.4 billion.

Net income is now projected to be in the range of $685 million to $705 million in 2007. This represents an increase of between 19% and 23% on an adjusted basis as compared to 2006 after one-time effects. On a reported basis, this translates into an increase in net income of between 28% and 31%. Previously, the Company expected net income in the range of $675 million to $695 million.

In addition, the Company still expects spending on capital expenditures and acquisitions to be approximately $650 million in 2007. The debt/EBITDA ratio is projected to be below 3.0 by the end of 2007.

Executive Officer of Fresenius Medical Care, commented: We are pleased to

report excellent financial results for the second quarter and six months ending

June 30, 2007. Contributing to the financial results, we have achieved an

organic growth rate of 8%. In addition we readjusted our service portfolio

focusing on profitability and expanded our product base in Asia-Pacific. We

continue to see many growth opportunities and upgraded our guidance which

reflects our confidence in the further profitable growth of our company

particularly in the international region. We remain focused on providing quality

care for our patients, working on all fronts to ensure that they achieve the

best possible clinical outcomes to maximize their overall health and well

Fresenius Medical Care will hold a conference call to discuss the results of the second quarter and the first half year of 2007 on Thursday, August 2, 2007, at 3.30pm CEDT / 9.30am EDT. The Company invites investors to view the live webcast of the conference call at the Company s website www.fmc-ag.com in the Investor Relations section. A replay will be available shortly after the call.

Fresenius Medical Care is the world s largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,500,000 individuals worldwide. Through its network of 2,209 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 171,687 patients around the globe. Fresenius Medical Care is also the world s leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).

For more information about Fresenius Medical Care visit the Company s website at www.fmc-ag.com.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.